Treating beyond trial eligibility: a pragmatic, prospective phase II study of first-line immunotherapy regimens in advanced non–small cell lung cancer patients with borderline performance status

Background Approximately 20-40% of patients with metastatic non-small cell lung cancer (mNSCLC) present with Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2, yet are systematically excluded from pivotal immunotherapy trials. Current guidelines recommend similar first-line regimens for PS0–1 and PS2 patients based on extrapolated data, creating clinical uncertainty. Methods This single-center, pragmatic pilot phase II study compares outcomes of standard first-line immunotherapy-based regimens between PS2 and PS0–1 patients with mNSCLC. Eligible patients receive NCCN-preferred regimens selected by treating providers per standard care. The primary outcome is 3-month progression-free survival (PFS), defined as the proportion without disease progression after four treatment cycles. Secondary outcomes include treatment-related adverse events and patient-reported quality of life changes. The study employs a non-inferiority design (margin –0.20 absolute difference in 3-month PFS proportion, α 0.05, 83% power) to assess whether PS2 patients achieve comparable early disease control to PS0–1 patients. Anticipated results We hypothesize that selected PS2 patients will demonstrate non-inferior 3-month PFS compared to PS0–1 patients when treated with standard immunotherapy-based regimens, with acceptable toxicity and quality of life outcomes. Conclusion This pragmatic trial addresses a critical evidence gap by prospectively evaluating whether performance status alone should preclude use of standard immunotherapy-based regimens in mNSCLC, providing data to inform shared decision-making for this underrepresented population. Clinical trial registration https://clinicaltrials.gov/study/NCT04253964 , identifier NCT04253964.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-11-13
DOI
https://doi.org/10.3389/fonc.2026.1929978
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Treating beyond trial eligibility: a pragmatic, prospective phase II study of first-line immunotherapy regimens in advanced non–small cell lung cancer patients with borderline performance status

Thomas William Lycan, John C. Hunting, Sarah N. Price, William J. Petty et al.
Frontiers in Oncology
Lung Cancer Treatments and Mutations
article

Treating beyond trial eligibility: a pragmatic, prospective phase II study of first-line immunotherapy regimens in advanced non–small cell lung cancer patients with borderline performance status

Thomas William Lycan, John C. Hunting, Sarah N. Price, William J. Petty, David Soto-Pantoja, Beverly J. Levine, Stefan Grant, Yaffa Ali, Haley W. Mabry
article en

Abstract

Background Approximately 20-40% of patients with metastatic non-small cell lung cancer (mNSCLC) present with Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2, yet are systematically excluded from pivotal immunotherapy trials. Current guidelines recommend similar first-line regimens for PS0–1 and PS2 patients based on extrapolated data, creating clinical uncertainty. Methods This single-center, pragmatic pilot phase II study compares outcomes of standard first-line immunotherapy-based regimens between PS2 and PS0–1 patients with mNSCLC. Eligible patients receive NCCN-preferred regimens selected by treating providers per standard care. The primary outcome is 3-month progression-free survival (PFS), defined as the proportion without disease progression after four treatment cycles. Secondary outcomes include treatment-related adverse events and patient-reported quality of life changes. The study employs a non-inferiority design (margin –0.20 absolute difference in 3-month PFS proportion, α 0.05, 83% power) to assess whether PS2 patients achieve comparable early disease control to PS0–1 patients. Anticipated results We hypothesize that selected PS2 patients will demonstrate non-inferior 3-month PFS compared to PS0–1 patients when treated with standard immunotherapy-based regimens, with acceptable toxicity and quality of life outcomes. Conclusion This pragmatic trial addresses a critical evidence gap by prospectively evaluating whether performance status alone should preclude use of standard immunotherapy-based regimens in mNSCLC, providing data to inform shared decision-making for this underrepresented population. Clinical trial registration https://clinicaltrials.gov/study/NCT04253964 , identifier NCT04253964.

Frontiers in OncologyVol. 16
Tulane University (US), Wake Forest University Health Sciences (US), Wake Forest University (US)
Comprehensive Cancer Center at Wake Forest Baptist Medical Center
Good health and well-being
Lung Cancer Treatments and Mutations
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon